Product Images Lenalidomide

The text provides statistical data for the survival probability and progression-free survival in a clinical trial with three different treatments. The survival probability table shows a 100% probability and HR values with respective Logrank p-values for each treatment. The progression-free survival chart shows the number of subjects at risk and PFS events for each treatment, which are Rd Continuous, RATB, and MPT.*

This is a table showing survival probability and overall survival rate of individuals in different treatment groups. The table includes the percentage of survival probability, the number of subjects at risk and overall survival in months. There are three different treatment groups mentioned: Rd Continuous vs MET, Rd Continuous vs R4T8 and, RarsemeT.*

This is a data table presenting the proportion of subjects in groups of 100, 75, 50, and 25, and their corresponding HR (Hazard Ratio) with a confidence interval of 95% and Log Rank p value. The table is related to the drug Lenalidomide when compared to a placebo, in terms of Time to Progression (measured in months) for a clinical study.*

This is a statistical analysis of a clinical trial comparing the effectiveness of the drug Lenalidomide with Placebo on the time of progression in patients. The results indicate that Lenalidomide when combined with Dex is significantly more effective than Placebo when combined with Dex in delaying disease progression. However, any other information about the population studied, the disease or the dose and duration of treatment is not available from the given text.*

This is a medication called Lenalidomide, which comes in capsules containing 10mg of the drug. It is important for pharmacists to dispense the medication guide to each patient due to the potential for human birth defects. The capsules contain FD&C Yellow No. 5 and should be stored at controlled room temperatures. The medication is distributed by Alvogen, Inc. and manufactured by Lotus Pharmaceutical Co., Ltd. There is no information available on the indications or therapeutic uses of this medication.*

This is a medication guide for Lenalidomide Capsules, manufactured by Lotus Pharmaceutical Co, Ltd. It contains 21 capsules, each with 15mg Lenalidomide. It is Rx only and should be stored at 20°C to 25°C (68°F to 77°F), with 15°C to 30°C excursions permitted. It contains FD&C Yellow No. 5 as a color additive. Dispense the medication guide to each patient. Usual dosage and administration can be found in the prescribing information.*

This is a description of Lenalidomide Capsules, NDC code 47781-488-77. Pharmacists are advised to give a medication guide to every patient. These capsules contain 25 mg Lenalidomide and have potential for human birth defects. Dosage information can be found in the prescribing information. They should be stored at 20°C to 25°C (68°F to 77°F), with excursions allowed to 15°C to 30°C (59°F to 86°F). These capsules are manufactured by Lotus Pharmaceutical Co., Ltd. in Taiwan and distributed by Alvogen, Inc. in Morristown, NJ. They are a product of India. The revision date for this information is 12/2021.*

This is a description of a medication called Lenalidomide which comes in capsule form. The pharmacist is instructed to dispense the medication guide with each patient. The medication has the potential to cause human birth defects, so caution is advised. The usual dosage is stated to be found in the prescribing information for dosing and administration. It should be stored at 20°C to 25°C and can be kept between 15°C to 30°C, excursions without compromising its quality. The medication is developed by Lotus Pharmaceutical Co., Ltd., Nantou Ciy, Nantou County 54066 Taiwan, and distributed by Alvogen, Inc. Morristown, NJ 07960 USA. It is a product of India.*